Terns Pharmaceuticals (TERN)
(Real Time Quote from BATS)
$7.46 USD
-0.07 (-0.93%)
Updated Jul 9, 2024 01:16 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TERN 7.46 -0.07(-0.93%)
Will TERN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TERN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TERN
Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?
Wall Street Analysts Believe Terns Pharmaceuticals (TERN) Could Rally 136.44%: Here's is How to Trade
TERN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Terns Pharmaceuticals, Inc. (TERN) Is Up 15.12% in One Week: What You Should Know
Take the Zacks Approach to Beat the Market: Uber, Baidu, AssetMark in Focus
Are You Looking for a Top Momentum Pick? Why Terns Pharmaceuticals, Inc. (TERN) is a Great Choice
Other News for TERN
Tern Plc Shareholders Vote Against Key Resolution
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
Terns Pharmaceuticals to highlight data supporting TERN-501
Terns Pharmaceuticals participates in a conference call with JPMorgan
Terns Pharmaceuticals participates in a conference call with JPMorgan